Depression is a recurring illness that often begins in early adulthood, and current drug treatments fail to help many patients because doctors cannot predict who will respond. This study addresses a critical gap: why some patients improve on antidepressants like SSRIs while others do not. The researchers will use two brain imaging techniques—magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI)—to track how the neurotransmitter serotonin interacts with glutamate in the brain, and how SSRIs alter the brain networks that process emotional information. If successful, this work could make depression treatment more precise. Instead of a trial-and-error approach that can take months, doctors might one day use brain scans to predict which patients will benefit from SSRIs, saving time and reducing suffering. The research also targets the fundamental biology of mood regulation, which could eventually guide the development of entirely new classes of antidepressants. For now, the project is primarily curiosity-driven—it seeks to understand the biochemical and neural mechanisms of depression, with the practical payoff of better treatment prediction as a longer-term goal.
View original technical description
Clinical depression is a common illness, often beginning in early adulthood, which can recur throughout a lifetime. The recurrent nature of clinical depression, together with the burden it places on patients and their families, makes this condition one of leading medical causes of suffering and disability. Understanding the biochemical changes in the brain in depression will help us devise better treatments and also improve efforts at prevention. A neurotransmitter called serotonin (5-HT) plays an important role in both the causation of depression and in current drug treatments. In this study we will use advances in brain imaging to study how 5-HT acts in the brain to alter mood. For example we will use magnetic resonance spectroscopy (MRS) to see how 5-HT interacts with special neurons in the brain that use a chemical messenger called glutamate. We believe that the interactions between 5 HT and glutamate may be very important in helping us understand the cause of depression and in developing more effective methods of treatment. A major problem in the treatment of depression is the unpredictability of response to current drug treatments; some patients do well, others are not helped very much. We believe that antidepressants which work through 5-HT such as the selective serotonin re-uptake inhibitors (SSRIs) may produce their therapeutic effects by acting on the way the brain analyses emotional information. The use of functional magnetic resonance imaging (fMRI) allows us to examine the brain networks involved in emotional experience. We will use therefore use fMRI to study how these brain networks are influenced by SSRIs in depressed patients and whether the changes we see enable us to predict those patients who will do well with treatment.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know